{"title":"治疗需要恢复砷化合物","authors":"David Bradley","doi":"10.1016/S1461-5347(00)00318-7","DOIUrl":null,"url":null,"abstract":"<div><p>An arsenic compound<span>, previously used as an insecticide<span>, is set to become the latest addition to the armoury for treating a rare form of leukaemia. On 26 September 2000, the FDA announced the approval of Trisenox (arsenic trioxide) for the treatment of acute promyelocytic leukaemia (APL), which affects approximately 2000 people each year in the USA.</span></span></p></div>","PeriodicalId":80125,"journal":{"name":"Pharmaceutical science & technology today","volume":"3 12","pages":"Page 401"},"PeriodicalIF":0.0000,"publicationDate":"2000-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S1461-5347(00)00318-7","citationCount":"10","resultStr":"{\"title\":\"Therapeutic needs revive arsenic compound\",\"authors\":\"David Bradley\",\"doi\":\"10.1016/S1461-5347(00)00318-7\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>An arsenic compound<span>, previously used as an insecticide<span>, is set to become the latest addition to the armoury for treating a rare form of leukaemia. On 26 September 2000, the FDA announced the approval of Trisenox (arsenic trioxide) for the treatment of acute promyelocytic leukaemia (APL), which affects approximately 2000 people each year in the USA.</span></span></p></div>\",\"PeriodicalId\":80125,\"journal\":{\"name\":\"Pharmaceutical science & technology today\",\"volume\":\"3 12\",\"pages\":\"Page 401\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2000-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1016/S1461-5347(00)00318-7\",\"citationCount\":\"10\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pharmaceutical science & technology today\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1461534700003187\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmaceutical science & technology today","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1461534700003187","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
An arsenic compound, previously used as an insecticide, is set to become the latest addition to the armoury for treating a rare form of leukaemia. On 26 September 2000, the FDA announced the approval of Trisenox (arsenic trioxide) for the treatment of acute promyelocytic leukaemia (APL), which affects approximately 2000 people each year in the USA.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
